在服用抗药的患者中,费洛迪平的生物可用性降低
S Capewell1, S Freestone, J A Critchley
1Department of Clinical Pharmacology, Royal Infirmary, Edinburgh.
Lancet (London, England)
|August 27, 1988
概括
接受抗治疗的患者显示费洛迪平的生物可用性显著降低. 对于接受酶诱导抗治疗的人来说,需要更高的费洛迪平剂量来达到治疗性血度.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
背景情况:
- 费洛迪平是一种二皮里丁抗体,具有广泛的第一通肝新陈代谢.
- 费洛迪平的正常口服生物利用率约为15%.
研究的目的:
- 为了研究费洛迪平在患有微体酶诱导由于慢性抗治疗的患者中的处置.
- 为了比较felodipine在诱导患者和正常志愿者的血度和生物可用性.
主要方法:
- 对10名接受抗治疗的患者和12名年龄和性别匹配的健康志愿者给予单次5毫克口服费洛迪平剂量.
- 血费洛迪平度被测量以确定峰值度和曲线下的面积 (AUC).
主要成果:
- 与正常志愿者相比,患者的血费洛迪平度明显降低.
- 患者的平均峰值度为1.6nmol/l,对照组为8.9nmol/l.
- 患者的平均AUC为2.0nmol.h/l,对照组为30.0nmol.h/l,表明相对生物利用率仅为6.6%.
结论:
- 慢性抗治疗显著降低了费洛迪平的口服生物可用性.
- 服用酶诱导性抗药的患者需要更高的费洛迪平剂量才能达到治疗水平.
相关概念视频
Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
Bioavailability: Influencing Factors
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

